Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies.

Chinese clinical oncology·2026
Same author

Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC).

The oncologist·2026
Same author

Ciclopirox reprograms effector responses and modulates Notch1 activation in activated human T cells.

iScience·2026
Same author

Novel <i>N</i>-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting histamine receptor H1 to overcome colorectal cancer drug resistance.

Cancer drug resistance (Alhambra, Calif.)·2026
Same author

Continuous flow synthesis of MOF/nanocarbon composites.

Nanoscale·2026
Same author

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

The oncologist·2026

Related Experiment Video

Updated: May 10, 2025

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

16.2K

Protease activity-based nanobiosensors for early detection of pancreatic cancer.

Obdulia Covarrubias-Zambrano1, Deepesh Agarwal2, Madumali Kalubowilage3

  • 1Department of Cancer Biology, University of Kansas Medical School, Kansas City, KS, USA.

Medical Research Archives
|April 28, 2025
PubMed
Summary
This summary is machine-generated.

Early pancreatic cancer detection is now possible with ultrasensitive nanobiosensors. This new method analyzes serum biomarkers, achieving 96% accuracy in identifying localized pancreatic cancer. This breakthrough offers hope for improving survival rates for this deadly disease.

Keywords:
Nanomedicinebiophotonicshierarchical decision structureiron/iron oxide nanoparticleliquid biopsypancreatic cancer detection

More Related Videos

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

727
Detection of Protease Activity by Fluorescent Peptide Zymography
09:56

Detection of Protease Activity by Fluorescent Peptide Zymography

Published on: January 20, 2019

12.6K

Related Experiment Videos

Last Updated: May 10, 2025

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

16.2K
Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

727
Detection of Protease Activity by Fluorescent Peptide Zymography
09:56

Detection of Protease Activity by Fluorescent Peptide Zymography

Published on: January 20, 2019

12.6K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Pancreatic cancer has a low survival rate, often diagnosed late due to non-specific symptoms and organ location.
  • Early detection remains a significant challenge for improving patient outcomes.
  • Existing diagnostic methods lack the sensitivity for early-stage identification.

Purpose of the Study:

  • To develop and validate ultrasensitive nanobiosensors for early pancreatic cancer detection using serum biomarkers.
  • To assess the feasibility of using protease and arginase activity for distinguishing pancreatic cancer from other conditions.
  • To achieve high accuracy in identifying localized pancreatic cancer through non-invasive serum analysis.

Main Methods:

  • Development of ultrasensitive nanobiosensors using Fe/Fe3O4 nanoparticles, cyanine 5.5, and designer peptides.
  • Detection of protease/arginase activity in serum samples from patients with localized cancer, metastatic cancer, pancreatitis, and healthy controls (n=159).
  • Analysis of data using an optimized information fusion-based hierarchical decision structure for multi-class classification.

Main Results:

  • Eight nanobiosensors demonstrated ultrasensitive protease and arginase activity measurements.
  • The methodology achieved approximately 96% accuracy in detecting localized pancreatic cancer from serum samples.
  • Validated initial findings with a larger, diverse patient cohort.

Conclusions:

  • Ultrasensitive nanobiosensors show high potential for early pancreatic cancer detection via serum analysis.
  • The developed information fusion model effectively classifies pancreatic cancer stages.
  • This approach offers a promising tool for improving early diagnosis and patient survival rates.